Jasper Therapeutics (JSPR) Projected to Post Quarterly Earnings on Thursday

Jasper Therapeutics (NASDAQ:JSPR) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Jasper Therapeutics to post earnings of ($0.79) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 12:30 PM ET.

Jasper Therapeutics Stock Up 10.7%

NASDAQ JSPR opened at $1.34 on Thursday. Jasper Therapeutics has a twelve month low of $1.11 and a twelve month high of $7.19. The company has a market capitalization of $37.49 million, a price-to-earnings ratio of -0.23 and a beta of 3.08. The stock’s 50-day simple moving average is $1.59 and its two-hundred day simple moving average is $2.08.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Thursday, January 22nd. Rodman & Renshaw initiated coverage on shares of Jasper Therapeutics in a research note on Tuesday, January 13th. They set a “buy” rating and a $17.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.88.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new position in Jasper Therapeutics during the first quarter valued at $46,000. Engineers Gate Manager LP bought a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at about $78,000. Panagora Asset Management Inc. purchased a new stake in Jasper Therapeutics during the fourth quarter worth $35,000. Voleon Capital Management LP purchased a new position in Jasper Therapeutics in the third quarter valued at about $50,000. Finally, XTX Topco Ltd purchased a new stake in Jasper Therapeutics during the second quarter valued at approximately $152,000. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.